IRVING, Texas–(BUSINESS WIRE)–McKesson Corporation (NYSE: MCK) today announced that it has signed an agreement in principle to expand its partnership with CVS Health to distribute pharmaceutical products to mail-order and specialty pharmacies, retail pharmacies and to distribution centers until June 2027.
“We are excited to continue our longstanding relationship with CVS Health and appreciate the shared commitment to improving health outcomes for all patients,” said Brian Tyler, Chief Executive Officer of McKesson. “We are privileged to extend our partnership for more than 20 years to continue to develop value propositions for patients using our diverse set of differentiated assets and capabilities.
Additionally, McKesson will release its second quarter fiscal 2023 financial results after market close on Tuesday, November 1, 2022. The company will host a live webcast of the earnings conference call for investors at 4:30 p.m. ‘Is, in order to review its financial results. .
The live webcast will be available on McKesson’s Investor Relations website at http://investor.mckesson.com, along with the company’s earnings press release, financial tables and slide presentation.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to improving healthcare outcomes for patients worldwide. Our teams partner with biopharmaceutical companies, healthcare providers, pharmacies, manufacturers, governments and others to provide information, products and services to make quality healthcare more accessible and affordable. Learn more about McKesson’s impact on virtually every aspect of healthcare at McKesson.com and read Our Stories.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to an agreement in principle. Readers should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, we undertake no obligation to update or revise our forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. Although it is impossible to predict or identify all of these risks and uncertainties, we encourage investors to read the risk factors described in our most recent annual and periodic report filed with the Securities and Exchange Commission. Risk factors related to the anticipated definitive contract include, but are not limited to: there could be delays in signing a definitive contract due to protracted negotiations; the parties may not sign a definitive contract for the extension of the term; and we may not realize all of the financial and operational benefits that we expect from a contract renewal.